Ontology highlight
ABSTRACT:
SUBMITTER: Bouchema TSE
PROVIDER: S-EPMC9787286 | biostudies-literature | 2022 Nov
REPOSITORIES: biostudies-literature
Bouchema Tahar Sif Eddine TSE Annereau Maxime M Vieillard Victoire V Boquet Raphael R Coelho Gisele Abreu GA Castelli Florence F Solgadi Audrey A Paul Muriel M Yagoubi Najet N Secretan Philippe-Henri PH Do Bernard B
Pharmaceutics 20221130 12
Selumetinib is administered orally in capsule form and is indicated for the treatment of neurofibromatosis. To facilitate dosage adjustments, liquid preparations, such as solutions or suspensions, are to be developed. This led, first, to determine the stability profile of soluble or dispersed selumetinib and, secondly, to look for ways to stabilize the active substance. The degradation kinetics of selumetinib as a function of stress conditions were determined and compared. The degradation produc ...[more]